Limbrel250® and Limbrel500® – Safety communication
December 4, 2017 – The FDA recommended that Primus Pharmaceuticals voluntary recall Limbrel (flavocoxid/citrated zinc bisglycinate) due to serious adverse events, including drug-induced liver injury and hypersensitivity pneumonitis.
Download PDF
